CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.

@article{Chaudhry2010CYP2C91BPP,
  title={CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.},
  author={Amarjit Singh Chaudhry and Thomas J. Urban and Jatinder Lamba and Angela K. Birnbaum and Rory P. Remmel and Murali Subramanian and Stephen C Strom and Joyce H S You and Dalia Kasperavi{\vc}iūtė and Claudia B Catarino and Rodney A. Radtke and Sanjay M. Sisodiya and D. B. Goldstein and Erin G. Schuetz},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2010},
  volume={332 2},
  pages={
          599-611
        }
}
The commonly prescribed antiepileptic drug phenytoin has a narrow therapeutic range and wide interindividual variability in clearance explained in part by CYP2C9 and CYP2C19 coding variants. After finding a paradoxically low urinary phenytoin metabolite (S)/(R) ratio in subjects receiving phenytoin maintenance therapy with a CYP2C9*1/*1 and CYP2C19*1/*2 genotype, we hypothesized that CYP2C9 regulatory polymorphisms (rPMs), G-3089A and -2663delTG, in linkage disequilibrium with CYP2C19*2 were… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 35 REFERENCES

Similar Papers

Loading similar papers…